Microbot Medical Showcases Landmark Robotic Endovascular Procedures

Microbot Medical ( (MBOT) ) has issued an announcement.

On March 26, 2026, Emory Healthcare and Microbot Medical announced that Emory interventional radiologists successfully performed robotic peripheral endovascular procedures using Microbot’s LIBERTY Endovascular Robotic System. The cases included the world’s first robotic prostatic artery embolization for benign prostatic hyperplasia and the first robotic Y-90 radioembolization mapping for liver cancer, demonstrating the system’s use across multiple complex indications.

Clinicians reported that LIBERTY improved navigation in challenging anatomy and enabled more precise, personalized treatment delivery, while aiming to reduce radiation exposure and physical strain and improve procedural efficiency. The milestone follows the limited market release of LIBERTY in November 2025 and precedes its planned full market launch in April 2026, underscoring growing clinical adoption that could strengthen Microbot’s position in the endovascular robotics market and expand patient access to minimally invasive care.

The most recent analyst rating on (MBOT) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.

More about Microbot Medical

Microbot Medical Inc. is a commercial-stage medical device company specializing in advanced robotic technology for endovascular procedures. Its flagship product, the LIBERTY Endovascular Robotic System, is the world’s first FDA-cleared, single-use, remotely operated robotic solution for peripheral endovascular interventions, targeting greater precision, efficiency and safety in vascular care.

Average Trading Volume: 1,959,153

Technical Sentiment Signal: Hold

Current Market Cap: $169.9M

Find detailed analytics on MBOT stock on TipRanks’ Stock Analysis page.